GLP-1 clinical trials in Tennessee: 26 recruiting now

26 GLP-1 clinical trials are recruiting at 41 sites in 13 cities across Tennessee. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Tennessee

1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   2 sites in Tennessee

   • West Tennessee Research Institute, Jackson. 731-633-0145
   • AARA Clinical Research - Murfreesboro Medical Clinic, Murfreesboro. 480-626-6650

2. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Tennessee

   • Vanderbilt University Medical Center, Nashville. 615-421-3082

3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

   Who can join. Adults 18+, have psoriasis, BMI 27+.

   1 site in Tennessee

   • DelRicht Research - Thompson's Station, Smyrna. 629-895-1775

4. Tirzepatide in PWS, HO and GNSO

   Phase 4. Run by Grace Kim. Registry number NCT06901245.

   A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Prader-Willi syndrome lose weight.

   Who can join. Adults 18 to 26, have Prader-Willi syndrome, BMI 30+.

   1 site in Tennessee

   • Vanderbilt University Medical Center, Nashville. 6158754274

5. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   5 sites in Tennessee

   • Jackson Clinic, Jackson
   • Holston Medical Group, Kingsport
   • CNS Healthcare, Memphis
   • HealthStar Physicians, PC, Morristown
   • Clinical Research Associates, Nashville

6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   3 sites in Tennessee

   • ClinSearch, LLC, Chattanooga. 833-602-2368
   • Innovative Clinical Research, Clarksville. 833-602-2368
   • Vanderbilt University Medical Center, Nashville. 833-602-2368

7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   3 sites in Tennessee

   • ClinSearch, LLC, Chattanooga. 833-602-2368
   • Innovative Clinical Research, Clarksville. 833-602-2368
   • Vanderbilt University Medical Center, Nashville. 833-602-2368

8. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   2 sites in Tennessee

   • Galen Medical Group - Galen Hepatology, Chattanooga. 423-653-0842
   • Gastro One (Walnut Run Road), Cordova

9. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

   Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

   2 sites in Tennessee

   • The Jackson Clinic, Jackson. 731-660-8396
   • East Coast Institute for Research - Jefferson City, Jefferson City

10. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Tennessee

    • Research Site, Memphis
    • Research Site, Morristown

11. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Tennessee

    • University Diabetes & Endocrine Consultants, Chattanooga. 833-602-2368
    • LifeDoc Research, PLLC, Memphis. 833-602-2368

12. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Tennessee

    • Vanderbilt Health One Hundred Oaks, Nashville. 615-322-6000

13. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Tennessee

    • Vanderbilt Health One Hundred Oaks, Nashville

14. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Tennessee

    • Gastroenterology Center Of The Midsouth, Cordova

15. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Tennessee

    • Gastroenterology Center Of The Midsouth, Cordova

16. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Tennessee

    • AMR Clinical, Knoxville. 865-305-9100

17. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Tennessee

    • LifeDoc Health, Memphis

18. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    3 sites in Tennessee

    • Holston Medical Group_Bristol, Bristol
    • Holston Medical Group, Kingsport
    • Clinical Research Associates, Nashville

19. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Tennessee

    • Quality Medical Research, Nashville. 615-835-4750

20. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. Run by T. John Winhusen, PhD. Registry number NCT06651177.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in Tennessee

    • Vanderbilt University Medical Center, Nashville. 615-585-9889

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact